Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BRNS Barinthus Biotherapeutics Plc.
- Stocks
- Healthcare
- NASDAQ: BRNS
Price (delayed)
$0.944
Market cap
$38.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.64
Enterprise value
-$50.58M
vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed
Highlights
Barinthus Biotherapeutics's quick ratio has increased by 17% from the previous quarter and by 17% YoY
Barinthus Biotherapeutics's EPS has increased by 11% YoY but it has decreased by 6% from the previous quarter
The net income has grown by 8% YoY but it has contracted by 7% from the previous quarter
The equity has contracted by 11% from the previous quarter and by 11% YoY
Key stats
What are the main financial stats of BRNS
Market
Valuations
Earnings
Shares outstanding
40.34M
Market cap
$38.08M
Enterprise value
-$50.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.33
Price to sales (P/S)
2.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.38
Revenue
$14.97M
Gross profit
$14.97M
Operating income
-$71.66M
Net income
-$65.23M
EBIT
-$65.21M
EBITDA
-$56.91M
Free cash flow
-$32.61M
Per share
Balance sheet
Liquidity
EPS
-$1.64
EPS diluted
-$1.64
Free cash flow per share
-$0.81
Book value per share
$2.86
Revenue per share
$0.37
TBVPS
$3
Total assets
$142M
Total liabilities
$26.4M
Debt
$11.92M
Equity
$115.49M
Working capital
$97.91M
Debt to equity
0.1
Current ratio
9.18
Quick ratio
8.4
Net debt/EBITDA
1.56
Margins
Efficiency
Dividend
EBITDA margin
-380.2%
Gross margin
100%
Net margin
-435.8%
Operating margin
-478.7%
Return on assets
-38.5%
Return on equity
-46.5%
Return on invested capital
-221.1%
Return on capital employed
-50.2%
Return on sales
-435.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BRNS stock price
How has the Barinthus Biotherapeutics stock price performed over time
Intraday
8.52%
1 week
8.88%
1 month
33.9%
1 year
-61.15%
YTD
-21.85%
QTD
-2.95%
Financial performance
How have Barinthus Biotherapeutics's revenue and profit performed over time
Revenue
$14.97M
Gross profit
$14.97M
Operating income
-$71.66M
Net income
-$65.23M
Gross margin
100%
Net margin
-435.8%
The operating margin has soared by 98% YoY but it has contracted by 5% from the previous quarter
The net margin has soared by 98% YoY but it is down by 7% QoQ
BRNS's operating income is up by 10% YoY but it is down by 5% from the previous quarter
The net income has grown by 8% YoY but it has contracted by 7% from the previous quarter
Price vs fundamentals
How does BRNS's price correlate with its fundamentals
Growth
What is Barinthus Biotherapeutics's growth rate over time
Valuation
What is Barinthus Biotherapeutics stock price valuation
P/E
N/A
P/B
0.33
P/S
2.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-3.38
Barinthus Biotherapeutics's EPS has increased by 11% YoY but it has decreased by 6% from the previous quarter
The stock's price to book (P/B) is 59% less than its 5-year quarterly average of 0.8 but 10% more than its last 4 quarters average of 0.3
The equity has contracted by 11% from the previous quarter and by 11% YoY
Efficiency
How efficient is Barinthus Biotherapeutics business performance
Barinthus Biotherapeutics's ROS has soared by 98% YoY but it has decreased by 7% from the previous quarter
The return on equity has declined by 14% year-on-year and by 10% since the previous quarter
BRNS's return on assets is down by 10% since the previous quarter and by 9% year-on-year
Barinthus Biotherapeutics's return on invested capital has decreased by 9% QoQ but it has increased by 2.8% YoY
Dividends
What is BRNS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BRNS.
Financial health
How did Barinthus Biotherapeutics financials performed over time
Barinthus Biotherapeutics's quick ratio has increased by 17% from the previous quarter and by 17% YoY
The current ratio rose by 14% QoQ and by 14% YoY
The debt is 90% lower than the equity
BRNS's debt to equity is up by 11% since the previous quarter and by 11% year-on-year
The equity has contracted by 11% from the previous quarter and by 11% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.